EIF3A
Eukaryotic translation initiation factor 3 subunit A
Also known as: EIF3, eIF3-p170, eIF3-theta, EIF3A_HUMAN, EIF3S10, KIAA0139, TIF32
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q14152
- Gene
- EIF3A
- Ensembl
- ENSG00000107581
- Chromosome
- 10
- Canonical length
- 1382 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
Enables RNA binding activity. Contributes to translation initiation factor activity. Involved in IRES-dependent viral translational initiation; formation of cytoplasmic translation initiation complex; and viral translational termination-reinitiation. Located in cytosol; nucleolus; and nucleoplasm. Part of eukaryotic translation initiation factor 3 complex. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
1382 residues, UniProt reviewed canonical sequence.
>Q14152|EIF3A
1 MPAYFQRPEN ALKRANEFLE VGKKQPALDV LYDVMKSKKH RTWQKIHEPI MLKYLELCVD
61 LRKSHLAKEG LYQYKNICQQ VNIKSLEDVV RAYLKMAEEK TEAAKEESQQ MVLDIEDLDN
121 IQTPESVLLS AVSGEDTQDR TDRLLLTPWV KFLWESYRQC LDLLRNNSRV ERLYHDIAQQ
181 AFKFCLQYTR KAEFRKLCDN LRMHLSQIQR HHNQSTAINL NNPESQSMHL ETRLVQLDSA
241 ISMELWQEAF KAVEDIHGLF SLSKKPPKPQ LMANYYNKVS TVFWKSGNAL FHASTLHRLY
301 HLSREMRKNL TQDEMQRMST RVLLATLSIP ITPERTDIAR LLDMDGIIVE KQRRLATLLG
361 LQAPPTRIGL INDMVRFNVL QYVVPEVKDL YNWLEVEFNP LKLCERVTKV LNWVREQPEK
421 EPELQQYVPQ LQNNTILRLL QQVSQIYQSI EFSRLTSLVP FVDAFQLERA IVDAARHCDL
481 QVRIDHTSRT LSFGSDLNYA TREDAPIGPH LQSMPSEQIR NQLTAMSSVL AKALEVIKPA
541 HILQEKEEQH QLAVTAYLKN SRKEHQRILA RRQTIEERKE RLESLNIQRE KEELEQREAE
601 LQKVRKAEEE RLRQEAKERE KERILQEHEQ IKKKTVRERL EQIKKTELGA KAFKDIDIED
661 LEELDPDFIM AKQVEQLEKE KKELQERLKN QEKKIDYFER AKRLEEIPLI KSAYEEQRIK
721 DMDLWEQQEE ERITTMQLER EKALEHKNRM SRMLEDRDLF VMRLKAARQS VYEEKLKQFE
781 ERLAEERHNR LEERKRQRKE ERRITYYREK EEEEQRRAEE QMLKEREERE RAERAKREEE
841 LREYQERVKK LEEVERKKRQ RELEIEERER RREEERRLGD SSLSRKDSRW GDRDSEGTWR
901 KGPEADSEWR RGPPEKEWRR GEGRDEDRSH RRDEERPRRL GDDEDREPSL RPDDDRVPRR
961 GMDDDRGPRR GPEEDRFSRR GADDDRPSWR NTDDDRPPRR IADEDRGNWR HADDDRPPRR
1021 GLDEDRGSWR TADEDRGPRR GMDDDRGPRR GGADDERSSW RNADDDRGPR RGLDDDRGPR
1081 RGMDDDRGPR RGMDDDRGPR RGMDDDRGPR RGLDDDRGPW RNADDDRIPR RGAEDDRGPW
1141 RNMDDDRLSR RADDDRFPRR GDDSRPGPWR PLVKPGGWRE KEKAREESWG PPRESRPSEE
1201 REWDREKERD RDNQDREEND KDPERERDRE RDVDREDRFR RPRDEGGWRR GPAEESSSWR
1261 DSSRRDDRDR DDRRRERDDR RDLRERRDLR DDRDRRGPPL RSEREEVSSW RRADDRKDDR
1321 VEERDPPRRV PPPALSRDRE RDRDREREGE KEKASWRAEK DRESLRRTKN ETDEDGWTTV
1381 RRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against EIF3A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 167 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 167 nTPM
- pancreas: 146 nTPM
- bone marrow: 114 nTPM
- tongue: 84 nTPM
- adipose tissue: 78 nTPM
- thymus: 73 nTPM
Single-cell type
- erythrocyte progenitors: 755 nCPM
- monocyte progenitors: 454 nCPM
- endometrial luminal cells: 454 nCPM
- pancreatic acinar cells: 446 nCPM
- megakaryocyte-erythroid progenitors: 436 nCPM
- suprabasal keratinocytes: 421 nCPM
Immune cell
- non-classical monocyte: 59 nTPM
- T-reg: 51 nTPM
- basophil: 49 nTPM
- intermediate monocyte: 42 nTPM
- classical monocyte: 38 nTPM
- myeloid DC: 36 nTPM
Brain region
- choroid plexus: 89 nTPM
- medulla oblongata: 83 nTPM
- hypothalamus: 79 nTPM
- thalamus: 78 nTPM
- spinal cord: 77 nTPM
- cerebral cortex: 76 nTPM
ReferencesPubMed · IEDB
Publications for EIF3A from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Pathogenic mechanisms of disease in idiopathic inflammatory myopathies: autoantibodies as clues.
2024 · Front Immunol · RCR 3.9 · 17 citations - Serum anti-EIF3A autoantibody as a potential diagnostic marker for hepatocellular carcinoma.
2019 · Sci Rep · RCR 1.1 · 28 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.13
- gnomAD pLI
- 1
- gnomAD missense Z
- 3.04
- DepMap mean gene effect
- -1.7
- DepMap dependency class
- pan
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- formation of cytoplasmic translation initiation complex
- IRES-dependent viral translational initiation
- negative regulation of ERK1 and ERK2 cascade
- translation reinitiation
- translational initiation
- viral translational termination-reinitiation
Molecular functions
- mRNA binding
- receptor tyrosine kinase binding
- RNA binding
- structural molecule activity
- translation initiation factor activity
Cellular components
- cytoplasm
- cytosol
- eukaryotic 43S preinitiation complex
- eukaryotic 48S preinitiation complex
- eukaryotic translation initiation factor 3 complex
- eukaryotic translation initiation factor 3 complex, eIF3e
- eukaryotic translation initiation factor 3 complex, eIF3m
- membrane
- microtubule
- multi-eIF complex
- nucleolus
- nucleoplasm
- postsynaptic density
Protein domainsUniProt · Pfam · InterPro
- Proteasome component (PCI) domain
- PCI domain
- Eukaryotic translation initiation factor 3 subunit A
- eIF3a, PCI domain, TPR-like region
- eIF3a, PCI domain, TPR-like region
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of EIF3A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads EIF3A as an antibody target. Whether an autoantibody or antibody against EIF3A could matter depends on whether native EIF3A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
EIF3A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label EIF3A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...